Trastuzumab is a type of medicine called an antibody. It's used to treat certain types of breast cancer. It works by blocking a protein called HER2 that helps cancer cells grow.
Every report comes from a Lived member, sent anonymously.
Have you tried Herceptin (Trastuzumab) for Breast Cancer?
Trastuzumab, first sold under the brand name Herceptin, is a targeted cancer medicine for adults whose cancer is HER2-positive. HER2 is a protein on the surface of cells that helps signal them to grow. In some cancers the cells make far too much of it, which tends to make the cancer grow faster. A lab test on a tumor sample (from a biopsy or surgery) shows whether this is the case, and trastuzumab is used only when the test is positive. In breast cancer, it is used for early-stage disease, usually alongside chemotherapy around the time of surgery to lower the chance the cancer comes back, and for breast cancer that has spread to other parts of the body. The intravenous form is also approved, together with chemotherapy, for HER2-positive stomach cancer or cancer where the esophagus meets the stomach that has spread and has not yet been treated. Several versions exist. Herceptin and its biosimilars, such as Trazimera, Kanjinti and Ogivri, are given into a vein; a biosimilar is a highly similar, FDA-approved version of a biologic medicine. Herceptin Hylecta is an injection under the skin approved for breast cancer only. Phesgo combines trastuzumab with pertuzumab, a second HER2-targeting antibody, in one injection.
Trastuzumab is a monoclonal antibody, a lab-made immune protein designed to lock onto one specific target. It attaches to HER2 on the surface of cancer cells. That slows the growth signals HER2 sends and also marks the cells so the immune system can attack them. Because it works through HER2, it is used only for cancers with extra HER2, which is why testing comes first. Trastuzumab is usually combined with chemotherapy, and the two work in different ways. It is not a chemotherapy drug itself, so it does not cause the same broad damage to fast-growing healthy cells, but it has its own risks, chiefly to the heart.
Intravenous trastuzumab is given as an infusion at a cancer center. The dose is based on body weight. The first infusion is a larger loading dose that takes about 90 minutes; later doses are smaller and can take as little as 30 minutes if the earlier ones went smoothly. Depending on the plan, infusions are weekly or every three weeks. Herceptin Hylecta is a fixed dose injected under the skin of the thigh over roughly two to five minutes, every three weeks. It is not dosed the same way as the IV form, and the two are not swapped without the oncologist's direction. The name can cause mix-ups. Kadcyla (ado-trastuzumab emtansine) and Enhertu (fam-trastuzumab deruxtecan) contain trastuzumab joined to a chemotherapy drug. They are different medicines with different doses and side effects, and are never substituted for plain trastuzumab. If a dose is missed, the care team decides how to resume, since a longer gap may mean repeating the loading dose.
Fever and chills during or soon after the first infusion are among the most common reactions, sometimes with headache, nausea or feeling achy. Later infusions are usually easier. Other common effects include diarrhea, tiredness, cough, rash, muscle or joint aches and more frequent infections. When trastuzumab is given with chemotherapy, it can deepen the drop in white blood cells that chemotherapy causes, so a fever during treatment should be reported promptly. The most important serious risk is weakening of the heart muscle, which can lead to heart failure. Contact the care team right away for new or worsening shortness of breath, cough, swelling in the ankles, legs or face, a racing or pounding heartbeat, sudden weight gain (more than 5 pounds in a day), dizziness or fainting. Serious infusion reactions and lung inflammation are uncommon but can be life-threatening; they usually appear during the infusion or within 24 hours afterward. The infusion team watches for these on site. After leaving, severe trouble breathing, wheezing, or swelling of the lips, tongue or throat needs emergency care: call 911.
Trastuzumab carries an FDA boxed warning, the agency's most prominent, for heart damage, serious infusion reactions, lung toxicity and harm to a pregnancy. The heart risk is highest when trastuzumab is given with or after anthracyclines, a group of chemotherapy drugs that includes doxorubicin, which can also strain the heart. Because trastuzumab stays in the body for months, an anthracycline is avoided for up to seven months after the last dose when possible, or given with close heart monitoring. People with existing heart disease or lung problems need this weighed carefully before starting. Trastuzumab can harm a developing baby, mainly by reducing the fluid around it, which has led to poor lung development and newborn deaths. A pregnancy test is done before starting, and people who could become pregnant need effective birth control during treatment and for seven months after the last dose. Anyone who becomes pregnant during that time should tell the care team so the pregnancy can be monitored. There is little information about breastfeeding, which is a decision to make with the oncologist.
Before treatment begins, the heart's pumping strength is measured with an echocardiogram (an ultrasound of the heart) or a MUGA scan, a nuclear imaging test. The key number is the ejection fraction, the share of blood the main pumping chamber pushes out with each beat; about 50% or higher is generally normal. It is usually rechecked every three months during treatment, and for early breast cancer every six months for at least two years afterward. If it drops significantly, trastuzumab is paused and the test repeated, and treatment may resume if the number recovers. Heart weakening can improve after stopping and with heart medicines, but it does not always fully recover. For early breast cancer, trastuzumab is given for a total of one year, continuing on its own after chemotherapy ends; a two-year course was tested and caused more side effects, so going beyond one year is not recommended. In large trials, adding it to chemotherapy clearly lowered the chance of the cancer returning and improved survival: after about eight years, roughly 87% of people who received it were alive, compared with about 79% who had chemotherapy alone. For cancer that has spread, it is continued as long as it keeps the cancer under control and is tolerated. In advanced stomach cancer the added benefit was more modest: median survival rose by roughly one and a half to two and a half months, depending on the analysis.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Herceptin (Trastuzumab), what you've noticed, or ask the community a question.